Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2021-06-01 Share Issue/Capital Cha…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Share Issue/Capital Change Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces the launch of an "Employee Shareholding Plan." It details the mechanics of the transaction, including the subscription price (€66.10), the discount (20%), the eligible employees, and the indicative timetable for subscription and settlement. This activity—involving the issuance or sale of shares specifically to employees as part of a savings plan—falls under capital structure changes or share transactions. Comparing the definitions, 'Share Issue/Capital Change' (SHA) covers general capital changes, while 'Transaction in Own Shares' (POS) covers share repurchase/issuance. Since this is a specific employee share offering, which often involves the issuance or sale of existing shares for employee benefit, POS is the most precise fit, as it relates directly to the movement of the company's own shares outside of a general public offering. It is not a general financing update (CAP) or a simple dividend notice (DIV).
2021-06-01 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Ipsen dated May 28, 2021, announcing that the FDA has accepted the New Drug Application (NDA) for palovarotene for the treatment of FOP, including details about priority review status and expected decision date (November 30, 2021). It also mentions acceptance by EMA and Swissmedic. The text discusses clinical trial data (MOVE trial), safety profiles, and future regulatory steps. This content is characteristic of a major corporate announcement regarding regulatory progress for a key drug candidate, which falls under the scope of an Earnings Release (ER) if it were periodic results, but since it is a specific, non-periodic regulatory milestone announcement, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides. However, given the format is a formal press release detailing a significant regulatory event (FDA acceptance/priority review) and clinical data, it functions as a key piece of investor information. Since there is no specific code for 'Regulatory Milestone Announcement' and it is not a full financial report (10-K, IR) or a transcript (CT), the most appropriate general category for significant, non-periodic corporate news that is not explicitly covered elsewhere (like M&A, Director Dealing, or Dividend) is Regulatory Filings (RNS). It is too detailed and long to be a simple Report Publication Announcement (RPA). Given the focus on regulatory acceptance and clinical data, RNS is the best fit as a catch-all for important, non-standard filings.
2021-05-28 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated May 28, 2021, announcing that the U.S. FDA has accepted the New Drug Application (NDA) for palovarotene for FOP and granted it Priority Review status. It details clinical trial data (MOVE trial), mentions regulatory validation by EMA and Swissmedic, and includes forward-looking statements and contact information typical of corporate news releases regarding product development milestones. This type of announcement, focusing on regulatory acceptance and clinical progress rather than comprehensive financial results or mandatory annual disclosures, fits best under the 'Earnings Release' (ER) category if it were quarterly results, but since it is a specific, material event announcement that isn't a standard financial report (10-K, IR, MRQ), it is most accurately classified as a general corporate announcement. Given the options, and since it is a significant, time-sensitive announcement about a product milestone, it is often categorized as an Earnings Release (ER) if it contains key performance indicators or updates, or sometimes as a Regulatory Filing (RNS) if it's a general disclosure. However, the content is a detailed update on regulatory progress and clinical data, which often accompanies or substitutes for an Earnings Release when discussing pipeline progress. Since it is not a transcript (CT), a formal financial report (10-K, IR), or a proxy statement (DEF 14A), and it is a major corporate update, 'ER' (Earnings Release, often used broadly for major operational/pipeline news) is a plausible fit, but 'RNS' (Regulatory Filings/General Announcement) is the safest fallback for non-standard, material news. Given the detailed nature of the announcement about FDA acceptance and clinical data, it functions as a major corporate update. I will classify it as an Earnings Release (ER) as these often include significant pipeline updates, or RNS as a general regulatory announcement. Since it is not explicitly about *earnings*, RNS is a better fit for a specific regulatory milestone announcement that isn't a core financial report.
2021-05-28 English
Informations privilégiées / Autres communiqués
AGM Information Classification · 1% confidence The document explicitly mentions the 'ASSEMBLEE GENERALE MIXTE DES ACTIONNAIRES DE LA SOCIETE IPSEN S.A. DU 27 MAI 2021' (Mixed General Meeting of Shareholders of IPSEN S.A. on May 27, 2021). It details that all resolutions were adopted, including the approval of a dividend payment and the renewal of director mandates. This content is characteristic of the official outcomes and materials presented during an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2021-05-27 French
Inside Information / Other news releases
AGM Information Classification · 1% confidence The document explicitly details the proceedings and outcomes of the 'COMBINED SHAREHOLDERS' MEETING OF IPSEN S.A. HELD ON 27 MAY 2021'. It confirms that all resolutions were approved, including dividend payment and director renewals. This content directly relates to the formal business conducted at an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document length is moderate, but the content is the meeting summary itself, not just an announcement of a report.
2021-05-27 English
Acquisition ou cession des actions de l'émetteur / Descriptif du programme de rachat
Transaction in Own Shares Classification · 1% confidence The document is a detailed description ('Descriptif') of a share repurchase program ('programme de rachat d'actions') being submitted for approval at the Annual General Meeting (AGM) on May 27, 2021. It outlines the objectives (market liquidity, covering stock plans, potential M&A), modalities, maximum price (€200 per share), and duration (18 months). This content directly relates to the company's capital structure management and transactions involving its own shares, which is the definition of 'Transaction in Own Shares' (POS). Although it is related to an AGM, the core subject is the share buyback plan itself, not the general meeting materials (AGM-R) or the voting results (DVA). Since the document details the mechanics and authorization request for buying back shares, POS is the most specific classification. The document length is substantial (7749 chars), indicating it is the primary disclosure, not just an announcement of a report (RPA/RNS).
2021-05-27 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.